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Conventional therapy of primary bone tumors includes surgical excision with wide resection, which
leads to physical and aesthetic defects. For reconstruction of bone and joints, allografts can be supple-
mented with mesenchymal stem cells (MSCs). Similarly, adipose tissue transfer (ATT) is supplemented
with adipose-derived stem cells (ADSCs) to improve the efﬁcient grafting in the correction of soft tissue
defects. MSC-like cells may also be used in tumor-targeted cell therapy. However, MSC may have adverse
effects on sarcoma development. In the present study, human ADSCs, MSCs and pre-osteoclasts were co-
injected with human MNNG-HOS osteosarcoma cells in immunodeﬁcient mice. ADSCs and MSCs, but not
the osteoclast precursors, accelerated the local proliferation of MNNG-HOS osteosarcoma cells. However,
the osteolysis and the metastasis process were not exacerbated by ADSCs, MSCs, or pre-osteoclasts.
In vitro proliferation of MNNG-HOS and Saos-2 osteosarcoma cells was increased up to 2-fold in the
presence of ADSC-conditioned medium. In contrast, ADSC-conditioned medium did not change the
dormant, quiescent state of osteosarcoma cells cultured in oncospheres. Due to the enhancing effect of
ADSCs/MSCs on in vivo/in vitro proliferation of osteosarcoma cells, MSCs may not be good candidates for
osteosarcoma-targeted cell therapy. Although conditioned medium of ADSCs accelerated the cell cycle of
proliferating osteosarcoma cells, it did not change the quiescent state of dormant osteosarcoma cells,
indicating that ADSC-secreted factors may not be involved in the risk of local recurrence.
& 2015 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
High-grade osteosarcoma is an aggressive primary malignant
bone tumor that is associated with a relatively good outcome;
since pre-operative and adjuvant combination chemotherapy has
been introduced the survival rate at 5 years for the non-metastatic
form at diagnosis has been 50–70% [1,2]. Osteosarcoma treatment
comprises surgical excision with wide resection of the tumor after
neo adjuvant chemotherapy. Adjuvant chemotherapy is thenGmbH. This is an open access art
pathologie de la Résorption
s, Faculté de Médecine, 1 rue
Trichet).adapted to histological response [3]. Concerning surgical techni-
ques, limb sparing is currently the preferred option. Reconstruc-
tion is dependent on resection site: if epiphysis cannot be pre-
served, mega prosthesis sometimes associated with an allograft is
typically used [4]. Otherwise, different conservative techniques are
described: massive autograft [5], vascularized autograft sometimes
associated with allograft or isolated allograft [6–8].
A permanent remission from osteosarcoma can be anticipated
after 10 years of event free survival [9–13], where after the pri-
mary challenge is to ameliorate the quality of life of patients suf-
fering from physical and aesthetic defects caused by tumor re-
section. For recovery of damaged soft tissues, plastic and re-
constructive surgery includes autologous grafts of adipose tissue.
Regenerative medicine promises new alternatives through the useicle under the CC BY-NC-ND license
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sident and multipotent cells. They have been originally identiﬁed
as a source of bone progenitor cells, but they also differentiate into
adipocytes, chondrocytes and myoblasts. Human MSCs may be
combined with scaffolds to increase bone healing as reported
previously [10,12]. Moreover, the use of MSCs cultured from bone
marrow to supplement an osteoarticular allograft in patients
treated after bone tumor resection did not increase the risk of local
tumor recurrence compared to control populations. Additionally,
MSCs can be modiﬁed to express tumor-targeted agents [14,15]
and used as “mesenkillers” [16].
Adipose tissue represents an alternative source of MSC-like
cells, avoiding the problems of pain, morbidity and low cell
number associated with bone marrow harvest [17]. In plastic and
reconstructive surgery, adipose tissue-derived stromal cells
(ADSCs) may be used to increase in situ survival of the autologous
adipose-tissue graft [18–23]. ADSC have also been utilized as cel-
lular delivery vehicles in bone reconstruction [24].
The use of adjuvant MSC-like cells in the treatment of osteo-
sarcoma may be an important therapeutic issue for patients with
lung metastasis associated with poor outcome (30% survival rate at
5 years) [25]. However, the impact of unmodiﬁed MSCs on tumor
progression remains unpredictable [26]. For instance, it has been
observed that rat and human MSCs can promote tumor growth
and metastasis in osteosarcoma models [27–30].
Facing a unique clinical case of osteosarcoma recurrence fol-
lowing autologous adipose-tissue transfer [30], we started to in-
vestigate the interactions between osteosarcoma and adipose tis-
sue by using pre-clinical experiments [30,64]. In the present re-
port, we compared the interactions of MNNG-HOS cells-induced
osteosarcoma with human ADSCs/MSCs and with human pre-os-
teoclasts. It is established that osteoclasts are involved in osteo-
sarcoma progression and are believed to either enhance or sup-
press metastases [31–33]. In this study, pre-osteoclasts did not
increase the tumor size and the lung metastasis. In contrast, ADSCs
and MSCs increased the size of MNNG-HOS-induced tumors, but
the metastasis process and rate of osteolysis were not exacerbated.
Paracrine effects of ADSCs were investigated on osteosarcoma cells
after culture in monolayer or oncospheres in order to observe the
effects on proliferative or quiescent cell stages. The addition of 50%
ADSC-conditioned medium signiﬁcantly increased the in vitro
proliferation of two osteosarcoma cell lines (MNNG-HOS and Saos-
2), whereas it did not decrease the proportion of cells in G0 phase.
These results suggest that ADSCs/MSCs may be safe in re-
constructive surgery after bone tumor resection and not involved
in the risk of local recurrence. However, ADSCs/MSCs do not ap-
pear to be good candidates for tumor-targeted cell therapy in os-
teosarcoma, given their enhancing effects on tumor progression.2. Materials and methods
2.1. Ethics statement
Adipose tissue samples were obtained from patients who un-
derwent abdominal liposuction in the plastic surgery department
of Nantes University Hospital (France). Bone marrow aspirates
were obtained from patients during orthopaedic surgical proce-
dures in Tours University Hospital (France). Blood samples were
obtained from the “Etablissement Français du Sang” in Nantes.
Oral consent was obtained from informed patients in accordance
with French law (Art. L. 1245-2 of the French public health code,
Law no. 2004-800 of 6 August 2004, Ofﬁcial Journal of 7 August
2004). The donors had no signiﬁcant medical history.
Experiments involving animals were conducted in accordance
with French guidelines (named “Charte nationale portant surl'éthique de l'expérimentation animale” by the French ethics
committee) and were approved by the regional committee on
animal ethics named CEEA.PdL.06, with project authorization
number 2013.4.
2.2. Cell lines and culture conditions
2.2.1. Osteosarcoma cell lines
MNNG-HOS and Saos-2 cells were purchased from the Amer-
ican Type Culture Collection (ATCC numbers CRL-1547 and HTB-85
respectively, Manassas, VA, USA). The cells were cultured in
Minimum Essential Medium alpha with nucleosides and 1 g/L
D-Glucose (Gibcos MEM α; Life technologies, Saint Aubin, France)
and supplemented with 10% fetal bovine serum (FBS, GE Health-
care, Vélizy-Villacoublay, France), at 37 °C in a humidiﬁed atmo-
sphere (5% CO2/95% air). For culture under anchorage-independent
conditions, medium was supplemented with 1.05% of methylcel-
lulose (R&D Systems, Lille, France) and 2.5% FBS. MNNG-HOS cells
were named LucF-HOS cells when they were modiﬁed to express
the Enhanced Fluorescent Green Protein (EGFP) and ﬁreﬂy luci-
ferase (LucF) genes as previously described [34].
2.2.2. Adipose- or bone marrow-derived stem cells
ADSCs were obtained from human fat samples which were
removed using the Coleman's procedure [30,35–37] and MSCs
were obtained from human bone marrow aspirates [38]. From
human fat or bone marrow samples, adherent cells were obtained
and at passage 3, they were characterized. As previously described,
[30,39] ﬂow cytometry analysis was performed to detect surface
markers (CD105, CD90, CD75, CD45, CD34 and CD3) and their
differentiation capacity towards osteogenic, adipogenic, chondro-
genic or leiomyocyte lineages was assessed. ADSCs were trans-
duced using EGFP-expressing lentiviral particles [34].
2.2.3. CD14 cells
They were obtained from human peripheral blood mono-
nuclear cells and selected with CD14 Microbeads by MACS tech-
nology (Miltenyi Biotec, Paris, France) [40]. To induce pre-osteo-
clast differentiation, CD14þ monocytes were cultured in alpha-
MEM containing 10% FBS, 25 ng/mL1 of human macrophage
colony stimulating factor (MCSF; from R&D Systems) and
100 ng/mL1 of human RANKL (kindly provided by Amgen Inc.,
Thousand Oaks, USA) for 7 days.
2.2.4. Conditioned media
ADSCs and MSCs were cultured to near conﬂuence with MEM α
medium supplemented with 10% FBS, washed twice and cultured
overnight in serum-free medium which was then collected and
frozen (20 °C), constituting ADSC- or MSC-conditioned medium
(CM).
2.3. Osteosarcoma model
2.3.1. Tumor induction
Four-week-old female athymic mice (NMRI nu/nu; Elevages
Janvier, Le Genest St Isle, France) were housed under pathogen-
free conditions at the Experimental Therapy Unit (Faculty of
Medicine, Nantes, France). The mice were anaesthetized by in-
halation of an isoﬂurane-air mix (2% for induction and 0.5% for
maintenance, 1 L/min) before any surgical manipulation and by
intraperitoneal injection of a ketamine-xylazine mix (16 mg/kg
and 66 mg/kg respectively) for bioluminescence measurements.
Osteosarcoma development was induced into the tibial anterior
muscle, by injection of 2106 MNNG-HOS cells, alone or with
ADSCs, MSCs or pre-osteoclasts at indicated ratios. Tumor volume
was calculated with the formula (l2xL)/2 where l and L represent
P. Avril et al. / Journal of Bone Oncology 5 (2016) 5–14 7the smallest and largest diameter respectively.
2.3.2. Histology analysis
Tumor samples were ﬁxed in 10% buffered formaldehyde and
then decalciﬁed in 4% EDTA 0.2% paraformaldehyde (PFA, pH 7.4)
buffer for 4 weeks. After embedding in parafﬁn wax, 5 μm-thick
sections were stained with Haematoxylin–Eosin–Safran (HES).
Human nucleus detection was performed using a digoxin-labeled
human locked nucleic acid Alu probe (Exiqon, Vedbaek, Denmark)
as described previously [10]. Brieﬂy, 70 nM Alu was hybridized on
histological sections following DNA denaturation, in a buffer con-
taining 4 X SSC (S6639, Sigma Aldrich, St. Quentin Fallavier,
France), 50% deionized formamide, 1 X Denhardt's solution, 5%
dextran sulfate and 100 mg/mL Salmon sperm DNA, for 19 h at
56 °C. Finally, the Alu probe was detected by peroxidase-based
immunohisto-chemical procedure. For Tartrate-Resistant Acid
Phosphatase (TRAP) detection slides were incubated 1 h in a
1 mg ml1 naphthol AS-TR phosphate, 60 mmol l1N,N-di-
methylformamide, 100 mmol l1 sodium tartrate and 1 mg ml1
Fast Red TR salt solution (Sigma Aldrich, Saint Quentin Fallavier,
France) and counterstained with haematoxylin. EGFP detection
was observed on frozen sections with ﬂuorescence microscopy
directly or after immunostaining using mouse monoclonal to GFP
primary antibody (Abcam, Paris, France) and Alexa Fluor 594 goat
anti-mouse IgG (Life Technologies, Saint-Aubin, France).
2.3.3. Lung metastasis detection
Lungs were systematically observed for macroscopic nodules at
necropsy. Macroscopic detection was completed by biolumines-
cence detection for tumor models induced with luciferase-ex-
pressing MNNG-HOS cells. The animals were placed individually in
an induction chamber, and anaesthesia was induced with 3% iso-
ﬂurane in oxygen. Then, mice were intra-peritoneally injected
with 3 mg D-Luciferin (Interchim, Montluçon, France) in 250 ml of
water, based on 25 g weight. After 7 min, mice were sacriﬁced for
quick extraction of the lungs, which were placed into a photon
Imager NightOWL LB 981 (Berthold technologies, Thoiry, France).
Bioluminescence acquisition was performed for two 1.5 min. The
BLI is expressed as photons per pixel per second after background
subtraction.
2.3.4. Micro-computed tomography (mCT)
Mouse tibiae were ﬁxed in 10% buffered formaldehyde and
scanned with a high resolution X-ray micro–computed tomo-
graphy Skyscan 1076 (Skyscan, Kontich, Belgium) using the fol-
lowing parameters: pixel size 18 mm, 50 kV, 0.5 mm Al ﬁlter, for
15 min. The 3D reconstruction was analyzed using the NRecon
software. Bone parameters following the bone ASBMR nomen-
clature were quantiﬁed using the CTan software (Skyscan) and
performed on 2 mm of tibia from the ﬁbula insertion point.Table 1
List of genes analyzed by real time RT-PCR. Genes are presented with ofﬁcial gene sym
sequences used to perform the analyses are indicated.
Ofﬁcial Symbol Ofﬁcial full name;Other name
ACTB Actin beta
GAPDH Glyceraldehyde-3-phosphate dehydrogenase
POU5F1 POU class 5 homeobox 1; OCT4
SOX2 SRY (sex determining region Y)-box 2
NANOG NanogHomeobox
RUNX2 Runt-related transcription factor 2; CBFA1
SOX9 SRY (sex determining region Y)-box 9
PPARG Peroxisome proliferator-activated receptor gamma
FABP4 Fatty acid binding protein 4
MYC Myelocytomatosis viral oncogene homolog2.4. Cell viability
Three thousand cells per well were seeded into 96-well plates
and after the appropriate culture period, WST-1 reagent (Roche
Diagnostics, Meylan, France) was added to each well and in-
cubated for 15 h at 37 °C; absorbance was read at 490 nm. During
the culture period, medium was supplemented with fat-CM or
ADSC-CM or recombinant human leptin as indicated (R&D Sys-
tems) or with an antibody directed against the subunit gp130 of
IL-6 family receptor (10 mg/mL; clone BK5 from Diaclone, Be-
sançon, France) as described [41].
2.5. Cell cycle analysis
Subconﬂuent cells were treated as indicated and labeled with
propidium iodide [42]. FITC-coupled mouse anti-human Ki-67
antibody or irrelevant isotype antibody for control (BD Pharmin-
gen, France) was eventually added before DNA staining with pro-
pidium iodide. Cell cycle distribution based on 2n or 4n DNA
content was analyzed by ﬂow cytometry (Cytomics FC500; Beck-
man Coulter, France) and 20,000 events were analyzed with
MultiCycle AV Software, Windows version (Phoenix Flow System;
San Diego, CA, USA) and CXP Analysis software version 2.2
(Beckman Coulter).
2.6. Multiplex assay
Quantiﬁcation of soluble factors listed in Fig. 3c was performed
using the Luminex technology (Bio-Plex Pro Assays, Bio-Rad,
Marnes la Coquette, France) according to the manufacturer's
instructions.
2.7. Reverse Transcription and Quantitative PCR
RNA was extracted using NucleoSpin RNA II (Machery-Nagel,
Düren, Germany). Reverse transcription (RT) was performed using
2 mg of total RNA and ThermoScript RT (Invitrogen Life Technolo-
gies). Then 20 ng of cDNA were ampliﬁed using the IQ SYBR Green
Supermix (Bio-Rad) with primers. Gene names and primer se-
quences are indicated in Table 1. Quantitative analysis was per-
formed with the iCycler iQ Real-time PCR Detection System (Bio-
Rad). Relative fold change of gene expression was calculated fol-
lowing the delta delta Ct method [43]. The reference genes ACTB
and GAPDH were used for normalization.
2.8. Statistical analysis
GraphPad InStat v3.02 software (La Jolla, CA, USA) was used. In
vivo experimentation results were analyzed with the unpaired
nonparametric method and Dunn's multiple comparisons follow-
ing the Kruskal–Wallis test. A p value of less than 0.05 wasbols, corresponding full name and other used name. Forward and reverse primer
Sense primer Antisense primer
CCAACCGCGAGAAGATGA CCAGAGGCGTACAGGGATAG
TGGGTGTGAACCATGAGAAGTATG GGTGCAGGAGGCATTGCT
CAATTTGCCAAGCTCCTGA AGATGGTCGTTTGGCTGAAT
GTATCAGGAGTTGTCAAGGCAGAG TCCTAGTCTTAAAGAGGCAGCAAAC
ATGCCTCACACGGAGACTGT AAGTGGGTTGTTTGCCTTTG
GTGCCTAGGCGCATTTCA GCTCTTCTTACTGAGAGTGGAAGG
GTACCCGCACTTGCACAAC TCGCTCTCGTTCAGAAGTCTC
GACCTGAAACTTCAAGAGTACCAAA TGAGGCTTATTGTAGAGCTGAGTC
CCTTTAAAAATACTGAGATTTCCTTCA GGACACCCCCATCTAAGGTT
CACCAGCAGCGACTCTGA GATCCAGACTCTGACCTTTTGC
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3.1. MSC-like cells increase MNNG-HOS osteosarcoma growth with-
out exacerbation of osteolytic lesions and lung metastases
In order to know whether MSC-like cells can affect human
osteosarcoma growth, they were co-injected with MNNG-HOS
cells in mice. Adherent cells derived from human bone marrow or
adipose tissue displayed similar phenotype, being CD3, CD34 and
CD45 negative and CD73, CD90 and CD105 positive (Fig 1a). For
meeting the minimal criteria to deﬁne mesenchymal stem cells
[44], these cells were differentiated into at least three different
lineages as previously shown [30,39]. MSCs or ADSCs have induced
a similar increase in the growth of MNNG-HOS-induced tumors
when they were co-injected in comparison with MNNG-HOS cells
alone (Fig. 1b). Furthermore we observed that a higher dose of
ADSCs induced a stronger growth of tumors (Fig. 2a). It was shown
that osteolysis enhances osteosarcoma growth in some murine
models [33,45]. Therefore, human osteoclast precursors, obtained
by stimulating CD14 positive cells with MCSF and RANKL were also
co-injected with MNNG-HOS cells. In contrast to human MSCs,
osteoclast precursors (CD14 positive cells) did not change tumor
growth (Fig. 3a). ADSCs, MSCs or CD14-positive cells did not in-
duce any tumor development when injected alone in mice.
As depicted in Fig. 2b, histology analysis showed very similar
characteristics with undifferentiated connective tissues in allFig. 1. Co-injection of MNNG-HOS cells with ADSCs and MSCs in athymic mouse. (a) ADS
in culture, cells were incubated with ﬂuorescent-coupled antibody directed against th
(b) Mean tumor volume evolution is presented for each group of mice (n¼8). HOS gr
HOSþMSCs were injected with 2.106 MNNG-HOS cells plus 5.105 ADSCs or MSCs, respect
day 30 (**: po0.01). (c) Microscanner images of tibiae bearing tumors are shown. Tumgroups. When EGFP-expressing ADSCs were co-injected with
MNNG-HOS cells in mice, EGFP was detected within the tumor
sections at day 10 post-tumor induction (Fig. 2c), but was no
longer detected at day 24. Starting with 33% of ADSCs, the MNNG-
HOS tumors contained less than 5% of ADSC at day 10 and none at
day 24 post-tumor induction. Therefore, the tumor mass grew
mostly through the MNNG-HOS cell proliferation and was not due
to ADSC proliferation.
Bone morphometry parameters for the tibia in contact to tu-
mors appeared very similar in all groups (Figs. 1c and 2d). In mice
that were co-injected with human pre-osteoclasts, Alu-sequence-
hybridization and TRAP staining were performed on serial sections
of mouse tibia bearing osteosarcoma at day 30 post-tumor in-
duction (Fig. 3b). Alu-sequence-hybridization signal identiﬁed the
human tumor cells, but did not co-localize with TRAP-positive
osteoclasts, indicating that no functional osteoclast may have de-
rived from human CD14 positive cells. This result correlated with
the fact that no increase in osteolysis was observed in MNNG-
HOSþCD14 group (data not shown).
Fireﬂy luciferase-expressing MNNG-HOS cells were used to
reveal lung metastases by bioluminescence. During the entire
animal imaging, strong signals at the primary-tumor injection
sites were detected, but signals in lungs were rarely detected
(Fig. 3c). Imaging of excised lung lobes detected metastases in all
animals, even though only half of the mice were identiﬁed with
macroscopic lung metastases. Bioluminescence quantiﬁcation of
lung metastases did not show signiﬁcant differences between the
groups injected with tumor cells alone or those with MSCs or
osteoclast precursors (Fig. 3c).Cs and MSCs were characterized by ﬂow cytometry analysis. After the third passage
e indicated clusters of differentiation (CD) and compared to unlabelled cells (CT).
oup was induced with 2.106 MNNG-HOS cells, while the groups HOSþADSCs and
ively. Signiﬁcant differences are indicated only for HOS groups with other groups at
or volume (mm3) and speciﬁc bone volume (%) are indicated.
Fig. 2. Co-injection of MNNG-HOS cells with ADSCs at ratio 10/1 or 2/1 in athymic mouse. (a) Tumor progression is reported for three groups of mice (n¼8) injected with
2 million MNNG-HOS cells either alone, or with 1 million or 0.2 million of ADSCs, named HOS, HOSþADSCs 10/1, and HOSþADSCs 2/1 respectively. Individual tumor
volumes are represented as dots and mean tumor volumes as red lines. Mean tumor volumes are presented for the three groups injected with MNNG-HOS cells and for the
group injected with 1 million ADSCs alone. Signiﬁcant differences between the MNNG-HOS and the HOSþADSCs 2/1 groups are indicated (*: po0.05; **: po0.01; ***:
po0.001). (b) Hematoxylin-Eosin-Safran staining on tumor sections revealed undifferentiated sarcomas. (c) EGFP-expressing ADSCs were detected at day 10 post-tumor
induction. EGFP was detected either indirectly by immunoﬂuorescence (red, Ac-EGFP) or by direct ﬂuorescence (green, EGFP). Nuclei were stained with DAPI (blue). Images
(red, green, blue) were combined using ImageJ software (Merge). Original magniﬁcations are indicated. (d) Tibia remodelling was analyzed when mean tumor volume
reached 3000 mm3 in each group, corresponding to day 45 or 35 after tumor induction for HOS and HOSþADSCs 2/1 groups, respectively. Mean parameters and SD are
shown for percent bone volume (BV/TV in %), bone surface/volume ratio (BS/BV) and trabecular thickness (Tb.Th).
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jection of human adipose tissue, MSCs and ADSCs increased the
tumor growth of primary human osteosarcoma, whereas human
osteoclast precursors did not. The metastasis process and the
massive osteolysis that is always observed on mouse tibia bearing
MNNG-HOS-induced tumors were not exacerbated by the co-in-
jection of human MSC-like cells or pre-osteoclasts.
3.2. Paracrine effect of MSC-like cells on proliferative or quiescent
osteosarcoma cells
MSC-like cells may support osteosarcoma growth through se-
creted growth factors and cytokines. Supporting this hypothesis,
the addition of 50% ADSC-conditioned medium (CM) without FBS
complementation signiﬁcantly increased the in vitro proliferation
of two osteosarcoma cell lines (MNNG-HOS and Saos-2) as mea-
sured by trypan blue counting or WST-1 assay (Fig. 4a). MSC-CM
also activated the in vitro proliferation of osteosarcoma cell lines.
As deciphered by cell cycle analysis (Fig. 4b), MSC-CM increased
the proportion of MNNG-HOS cells in the G2/M phase similarly to
10% FBS complementation in comparison to 0% FBS. Among 29cytokines/growth factors measured by multiplex assay (Fig. 4c),
we did not identify a paracrine mediator that would be present in
both MSC- and ADSC-CM, but that would not be an autocrine
mediator secreted by MNNG-HOS and Saos-2 cells. Vascular en-
dothelial growth factor (VEGF) concentrations were greater in
osteosarcoma cell-CM than in medium conditioned by MSCs. In-
terleukin-8 and -6 (IL-8 and IL-6) concentrations were higher in
medium conditioned by ADSCs than in osteosarcoma cell-CM or
MSC-CM. Similarly to what was observed using adipose tissue-CM
[64], the osteosarcoma cell proliferation induced by ADSC-CM was
not prevented by inhibition of IL-6 or IL-8 signaling with neu-
tralizing antibody directed against the gp130 subunit or the che-
mokine (C-X-C motif) receptor 1/2 respectively (data not shown).
Considering that MSC-like cells are only used following che-
motherapy and tumor resection for bone or soft tissue repair, it
may be of interest to test their paracrine effect on quiescent os-
teosarcoma cells rather than on proliferating ones. To this aim,
MNNG-HOS cells were cultured without anchorage, inducing the
formation of oncospheres (Fig. 5a), as done to isolate cancer stem
cells from osteosarcoma biopsies [46] or to induce a cancer stem
cell-like phenotype [47]. As expected [48], we observed a
Fig. 3. Co-injection of MNNG-HOS cells with MSCs or pre-osteoclasts in athymic mouse. (a) Evolution of median tumor volumes is reported for each group of mice (n¼6).
The HOS groups were injected with 2.106 MNNG-HOS cells, while the groups HOSþMSCs and HOSþCD14 were injected with 2.106 MNNG-HOS cells plus 1 million MSCs or
RANKL-MCSF-activated CD14 cells, respectively. Signiﬁcant differences between HOSþMSCs and HOS groups are indicated by single stars for po0.05. (b) TRAP staining and
Alu-sequence hybridization were performed on serial sections of tumors obtained 34 days after HOSþCD14 injection. Arrows indicate potential osteoclasts that were TRAP
positive (red staining) but negative for Alu hybridization (nuclei stained in blue). In contrast numerous Alu-positive nuclei corresponding to MNNG-HOS cells were stained in
brown. (c) Luciferase-activity was detected at day 34 after cell injections. One representative image of bioluminescence in vivo detection is shown for primary-tumor sites
(top left panel), for secondary-tumor sites at lungs using a cache for primary sites (top right panel) and for excised lung lobes (low panel). The quantiﬁcation of ex vivo
luciferase activity of lung lobes is expressed as photons per pixel per second (Ph/pix s) after subtraction of photon noise. Quantiﬁcation is showed for each animal (point) and
the mean value is showed for each group (bar). No signiﬁcant differences were observed between groups.
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transcription factors such as OCT4 (POU5F1; 4300 fold), SOX2
(450 fold) and NANOG (49 fold) for MNNG-HOS cells cultured in
oncospheres compared to those cultured in monolayers (Fig. 5b). A
concomitant down-regulation of osteogenic and chondrogenic
speciﬁc genes (0.33-fold for RUNX2 and 0.4-fold for SOX9) was
noted, while expression of adipogenic speciﬁc genes were slightly
increased (1.7-fold for PPARG and 2.4-fold for FABP4). Furthermore,
MNNG-HOS cells cultured in oncospheres slowed down their
proliferation as shown by the decrease of MYC expression (Fig. 5b)
and by the low proportion of MNNG-HOS cells that were detected
in S/G2/M phases (o15%) (Fig. 5c). Cell cycle analysis combining
DNA and Ki-67 staining also revealed a high proportion (30%) of
non-dividing cells corresponding to cells in G0 cell cycle phase in
oncospheres. However, FBS complementation enabled part of G0
cells to enter G1 phase (2-fold decrease of G0 cells). In contrast
ADSC- or MSC-CM did not decrease the proportion of cells in G0.
These results indicate that ADSCs and MSCs, through secreted
factors, may accelerate the cell cycle of proliferating osteosarcoma
cells, but may not change the quiescent state of dormant tumor
cells.4. Discussion
We have previously shown that murine MSC-like cells increased
tumor growth when they were co-injected with osteosarcoma cells in
mice. In this study, we demonstrate that osteosarcoma growth is also
supported by the co-injection of human MSC-like cells, either derived
from adipose tissue or bone marrow, but not by osteoclast precursors.
In tumors induced by the co-injection of MNNG-HOS cells and ADSCs,
ADSCs were not identiﬁed at the end of in vivo experiments. Soluble
factors produced by ADSC increased by up to 2-fold the in vitro pro-
liferation of two different osteosarcoma cell lines (MMNG-HOS and
Saos-2). These results indicate that ADSCs/MSCs may modulate the
early MNNG-HOS tumor development, at least partially through
paracrine effects as described for cancer-associated adipocytes and
breast cancer [49] or adipose tissue and osteosarcoma [64]. It has been
suggested that MSCs improve angiogenesis after an ischemic lesion
[50,51] or facilitate successful fat injection during surgery for breast
augmentation or reconstruction [19]. By stimulating neovasculariza-
tion, MSC-like cells may contribute to sarcoma growth [25,44]. VEGF
was identiﬁed in ADSC/MSC-conditioned medium but in concentra-
tions similar to MMNG-HOS/Saos-2 cell-conditioned medium. In
samples of MNNG-HOS-induced tumors which have otherwise
Fig. 4. MSC-like cell secreted factors on proliferation of osteosaroma cells in vitro. (a) Mitochondrial activity of MNNG-HOS or Saos-2 cells was measured after 24 h in
mediumwithout FBS (CT) or supplemented with ADSC-conditioned medium representing 10% or 50% of the total volume. Results are the means of 3 wells and are presented
as percentage of control (CT) with standard deviations. Signiﬁcant differences between CT and ADSC-CM are indicated (*: po0.05; ***: po0.001). (b) Cell cycle analysis of
MNNG-HOS cells was measured after 24 h in medium not supplemented (0%) or supplemented with FBS (10%) or MSC-CM (25%). The histograms represent cells numbers in
cell phases. Because only 3-2% of cells were identiﬁed in the sub-G0 phase, only the proportion of cells in the G0/G1, S and G2/M phases are indicated. (c) Quantiﬁcation of
different cytokines or growth factors using multiplex immunoassay in medium conditioned by MNNG-HOS, Saos-2 cells, ADSCs or MSCs. Interleukins (IL), chemokine ligands
(CCL and CXCL), growth factors (ﬁbroblast GF-2, vascular endothelial GF-A, platelet-derived GF-bb, tumor necrosis factor alpha, interferon gamma, leukemia inhibitory factor)
and adipokines (leptin, resistin, visfatin) were measured. #: not detected.
Fig. 5. MSC-like cell secreted factors on quiescent osteosaroma cells in vitro. (a) Representative image of spheres obtained with MNNG-HOS cells cultured under an an-
chorage-independent condition. Immunohistochemistry detection of Ki-67 revealed a high proportion of proliferating cells (450%). (b) Relative expression fold changes are
presented for mRNA of MNNG-HOS cells cultured either under anchorage (monolayer) or non-anchorage conditions (spheres). Gene name symbols with corresponding full
names are indicated in Table 1. Results are means of 3 samples and are presented with standard deviations. Signiﬁcant differences between the anchorage and non-
anchorage culture conditions are indicated (*: po0.05; ***: po0.001). (c) Dot plots present the % of MNNG-HOS cells in different cell cycle phases following DNA and Ki-67
detection by ﬂow cytometry. MNNG-HOS cells cultured in oncosphere were incubated for 48 h in medium not supplemented (0% FBS) or supplemented with 10% FBS (10%)
or 25% ADSC/MSC-CM. Results are representative of 3 independent experiments.
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VEGFA expression nor in tumor neovascularization (data not shown).
Bian et al. [27] have reported that human MSCs promoted Saos-2
osteosarcoma growth but through Interleukin 6 (IL-6) secretion. In the
present study, IL-6 and IL-8 were indeed detected in the ADSC-con-
ditioned medium. Nonetheless, they were not identiﬁed as the mo-
lecules that could mediate enhanced proliferation of MMNG-HOS and
Saos-2 cells. Similarly, basic ﬁbroblast growth factor (FGF-2) did not
enhance the proliferation of osteosarcoma cells in vitro (data not
shown), despite the fact that a role for FGF-2 in tumor progressionwas
suggested, especially in an original mouse model of osteosarcoma [52].
Other soluble factors that were not investigated in this study included
metalloproteinase 11 which can favor tumor progression, collagen VI
involved in the breast cancer-adipocyte interaction [53] and lysopho-
sphatidic acids implicated in development of bone metastases [54]. All
these factors may be implicated, possibly acting in combination, in
osteosarcoma cell proliferation.
Preclinical studies have shown that adipocytes and MSCs play
an important role in migration and dissemination of cancer cells
[55,56]. Concerning osteosarcoma, one publication has reported
that human MSCs injected through the caudal vein of mice bearing
Saos-2- induced an increase in tumor volume associated with
more severe osteolytic lesions and a higher rate of pulmonary
metastasis [29]. A similar pro-metastatic effect was observed with
rat MSCs injected intravenously in rats bearing osteosarcoma
[28,57], while co-implantation of rat MSCs and osteosarcoma cells
did not promote lung metastasis [28]. In the present study, we did
not observe an aggravation of osteolytic lesions and lung metas-
tases despite tumor growth increase following co-injection of
ADSCs/MSCs with MNNG-HOS cells in mice. Because the metas-
tasis process was not changed by ADSCs/MSCs injection in vivo,
ADSC-derived soluble factors were not tested in in vitro migration
assays of osteosarcoma cells.
Growth of osteosarcoma is supported by the bones micro-
environment including the activity of osteoclasts. The role of os-
teoclasts was demonstrated in osteosarcoma models through os-
teolysis blockage which enhanced tumor regression or allowed
tumor growth inhibition [33,58]. However, Endo-Munoz et al. [31]
have reported that the loss of osteoclasts in the early development
of osteosarcoma is associated with increased potential for osteo-
sarcoma cells to metastasize. Surprisingly in the present study, the
osteosarcoma development including local growth, lung metas-
tasis and osteolysis, were not changed by the early co-injection of
pre-osteoclasts (MCSF and RANKL-stimulated CD14 positive cells)
with MNNG-HOS cells in mice. This experiment did not conﬁrm
that osteoclasts could activate osteosarcoma growth or prevent the
metastasis process while no mature human osteoclasts could be
detected in vivo following co-injection.
MSC appear to have a dual nature, regarding their ability to
promote tumor growth and metastasis or to suppress tumor pro-
gression [26]. The reasons for the discrepant actions of MSCs on
tumor growth are under investigation but potentially may be at-
tributed to differences in tumor models, the dose or timing of MSC
injections, the animal host, or the inﬂammatory status of MSCs
[59]. In view of the enhancing effect of ADSCs/MSCs on the pro-
liferation of osteosarcoma cells both in vivo and in vitro, MSCs may
not be good candidates for osteosarcoma-targeted cell therapy.
Nonetheless, the models of MSC injection in rodents bearing
fast-growing tumors are unlikely useful for clinical application in
reconstructive surgery following chemotherapy and/or tumor re-
section. Aanstoos et al. [60] have recently tested MSC injection
after amputation in mice bearing osteosarcoma and showed that
MSC injection at the surgical site did not promote pulmonary
metastasis or local recurrence compared to no-MSC injection;
however MSC intravenous injection induced a faster development
of pulmonary metastasis. More than 20 years ago, Hernigou et al.supplemented bone allografts with autologous bone marrow from
the iliac crest and then started to use nucleated cells concentrated
from bone marrow aspirate. Following implantion of autologous
concentrated bone marrow cells including MSCs into 1873 patients
without malignancy, there was no excess of neoplastic events over
the expected number in a normal population [61]. Similarly, no
increased risk of neoplasia was reported in a cohort of more than
200 patients treated with MSCs for different regenerative medi-
cine applications [62]. Furthermore, Hernigou et al. reported that
the autologous concentrated bone marrow cell adjuvant therapy in
92 patients treated after bone tumor resection did not increase the
risk of local tumor recurrence compared to control populations
[63].
In the present study, the effect of ADSC-secreted factors were
tested on dormant cancer cells that could be present following
therapy. For this purpose, osteosarcoma cells were cultured in
oncospheres to induce a cancer stem cell-like phenotype [47]. We
observed that conditioned medium of ADSCs did not change the
quiescent state of dormant osteosarcoma cells when they were
cultured in oncospheres, while such medium accelerated the cell
cycle of proliferating osteosarcoma cells. This result indicates that
ADSC-secreted factors may not be involved in the local recurrence
by activation of cancer stem cells. This result combined with those
obtained with adipose tissue-secreted factors [64] is reassuring for
the complementation of adipose tissue transfer with ADSCs in
plastic reconstructive surgery, but further investigation using
preclinical models which mimic quiescent state of osteosarcoma
are still needed to warrant safe clinical use of ADSCs following
osteosarcoma resection.Grant support
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